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Abstract 
 
Understanding buffering mechanisms for various perturbations is essential for under-
standing robustness in cellular systems. Protein-level dosage compensation, which aris-
es when changes in gene copy number do not translate linearly into protein level, is one 
mechanism for buffering against genetic perturbations. Here, I present an approach to 
identify genes with dosage compensation by increasing the copy number of individual 
genes using the genetic tug-of-war technique. A screen of Saccharomyces cerevisiae 
chromosome I suggests that dosage-compensated genes constitute approximately 10% 
of the genome and consist predominantly of subunits of multi-protein complexes. Im-
portantly, because subunit levels are regulated in a stoichiometry-dependent manner, 
dosage compensation plays a crucial role in maintaining subunit stoichiometries. Indeed, 
changes in the levels of a complex were observed when its subunit stoichiometries were 
perturbed. I further analyzed compensation mechanisms using a proteasome-defective 
mutant and autophagy-defective mutants as well as ribosome profiling, which provided 
strong evidence for compensation by ubiquitin-dependent degradation but not by au-
tophagy and reduced translational efficiency. Thus, this study provides a systematic 
understanding of dosage compensation and highlights that this post-translational regula-
tion is a critical aspect of robustness in cellular systems. 
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Chapter 1 
 
General introduction 
 
1.1 Robustness of cellular systems 
Robustness in biological systems is a general trait of living cells and a fundamental 
feature involving the maintenance of stability during perturbation [1–4]. It is a universal 
challenge to cope with perturbations leading to fluctuations in biological processes be-
cause cells are exposed to changes in internal and external environments [5,6]. Under 
stress conditions, cells change gene expression levels in order to activate appropriate 
stress response mechanisms. By such mechanisms, stability in perturbed systems and 
growth is recovered, and finally cells adapt to stress conditions. While adaptation is a 
consequence of robustness, fragility indicates a lack of robustness. If cells experience 
one perturbation and develop responses to it, adaptation to the perturbation is possible. 
On the other hand, if cells are not able to buffer one perturbation and to develop re-
sponses to it, adaptation to the perturbation is impossible. At the same time, cells may 
lose and obtain a potential opportunity to adapt to the other perturbation in the former 
and latter cases, respectively. Therefore, this relationship is expressed as the trade-off 
between robustness and fragility. 
Changes in gene expression levels are achieved through various mechanisms 
in the whole process of gene expression (Figure 1.1). This is a source of stress response 
and adaptation as described above, so that one aspect of the cellular robustness to vari-
ous perturbations can be understood as a consequence of fluctuations in gene expression 
and buffering of fluctuations [5–8], as illustrated in Figure 1.2. For example, alterations 
in gene copy number are known as a source of such fluctuations, which is one of the 
hallmarks of cancer cells and the cause of Down’s syndrome [9]. Therefore, under-
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standing buffering mechanisms is essential to understanding the optimization of gene 
expression and adaptation to changes in environmental conditions. Investigations of 
mechanisms conferring robustness to cellular systems have proceeded by regarding a 
cell as a single system. In this context, each of the cellular elements (e.g., genome, 
transcriptome, proteome, metabolome) is recognized as a parameter in biological pro-
cesses. It is important to study changes in each of the parameters, which is representa-
tive of gene expression, in response to various perturbations because of the fact that in 
the face of perturbations gene expression dynamically changes to maintain cellular ho-
meostasis. This recognition is a philosophical foundation of Systems Biology. 
 
1.2 Consequences of genetic perturbations 
As a consequence of genetic perturbations in gene expression, protein synthesis and 
degradation deviate from the steady state. This cellular state has recently been proposed 
as proteome imbalance [10]. Protein overexpression leads to proteome imbalance and 
causes cellular defects depending on properties and functions of proteins [11]. The 
causal mechanisms have been classified into four types: resource overload, stoichiomet-
ric imbalance, promiscuous interactions, and pathway modulation [12]. Briefly, for 
example, resource overload, stoichiometric imbalance, promiscuous interactions, and 
pathway modulation may cause the protein burden effect, abnormal complex formation, 
sequestration of essential proteins, and abnormal regulation of transcription and signal-
ing pathway, respectively. These mechanisms are regarded as the primary ones respon-
sible for cellular defects due to protein overexpression. In this study, I focused on the 
stoichiometric imbalance as described below. 
Proteome imbalance has been proposed to cause proteotoxic stress through 
those mechanisms. Proteotoxic stress is induced by an increased burden on the systems 
for the protein quality control, including molecular chaperone networks and degradation 
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pathways, due to excess proteins [13,14]. As characteristic features of proteotoxic stress, 
cells with proteotoxicity are sensitive to inhibition of protein synthesis and folding and 
show metabolic alterations [15]. Proteotoxic stress is closely related with the formation 
of protein aggregates; indeed, proteins are prone to form aggregates in aneuploid yeast 
strains containing an extra chromosome [16]. Furthermore, a deletion of the deubiquiti-
nase gene UBP6 in the aneuploid strains decreased the number of cells with aggregates. 
While some aneuploid yeast strains were shown to grow very slowly, a deletion of 
UBP6 suppressed the proliferation defect of these strains [15]. These observations sug-
gest that activation of ubiquitin-dependent degradation of excess proteins rescues cell 
growth under genetic perturbations causing proteotoxic stress. 
 
1.3 Measurement of cell robustness against gene overexpression 
The molecular mechanisms conferring robustness to some biological processes have 
been studied (e.g., cell cycle, circadian clock). However, we lack a method allowing an 
assessment of robustness of cell fitness in global, systematic, and quantitative manners. 
This demand has been addressed by some studies, and the molecular and physiological 
phenotypes have been connected to achieve a global measurement of cell robustness 
[17–20]. For example, systematic investigations of the robustness in cellular systems 
have been performed by focusing on the effects of manipulating gene copy number on 
cell growth [18,19]. These studies based on gene copy number increase mainly used two 
different approaches: introducing a plasmid carrying an individual target gene [18] and 
generating aneuploidy of specific chromosomes [19]. The former study measured cell 
robustness to gene overexpression using a genetic technique termed genetic tug-of-war 
(gTOW), by which fragility to protein overproduction is indirectly and quantitatively 
assessed as an upper limit of gene copy number in Saccharomyces cerevisiae [18,21,22]. 
Moriya et al [21] developed the gTOW technique in order to measure cell robustness 
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against gene overexpression and shed light on how we can explore its quantitative as-
pects. The gTOW technique is a method of relative overexpression in contrast to the 
fact that a promoter-swapping technique (e.g., the use of GAL1 and TDH3 promoters) is 
one of the methods of absolute overexpression. A promoter-swapping technique in-
creases messenger RNA (mRNA) level and the increase strongly depends on the pro-
moter activity. As it is impossible to compare mRNA levels expressed from the native 
promoter and the non-native one in the same cells, we cannot determine the fold in-
crease in gene expression level. On the other hand, the gTOW technique, a method of 
the relative overexpression, allows us to measure how many folds the gene expression 
level increase compared with the native level. The relative overexpression method is 
useful to quantitatively assess robustness of cell systems against gene overexpression. 
The genome-wide gTOW analysis has revealed fragile points as a set of 115 dos-
age-sensitive genes that cause impaired growth when the gene copy number is slightly 
increased [18]. In other words, only 2% of the yeast genome (115 out of 5806 genes) is 
sensitive to gene dosage such that a copy number increase leads to breakdown of bio-
logical systems. Conversely, this result indicates that genetic perturbations to biological 
processes are generally buffered. However, the buffering mechanisms behind the ro-
bustness against gene overexpression remain to be investigated. On the other hand, the 
latter studies using aneuploid yeast and mammalian cells have also revealed fragility of 
cellular systems against gene copy number increase in a genome-wide manner [19]. 
Further analysis has shown that the fragility of aneuploid cells is caused by many genes 
on single additional chromosomes but not by the dosage-sensitive genes duplicated by 
ploidy changes [23]. Moreover, previous studies have demonstrated the effects of aneu-
ploidy on cell fragility (e.g., growth impairment caused by proteotoxic stress, hypersen-
sitivity to inhibitors of protein synthesis, folding, and degradation) [15,24,25], while an 
increase in individual gene copy number generally does not cause a defect in cell 
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growth [18]. These findings indicate differences of impact on cell robustness between 
many copies of a single gene and an additional chromosome. I thus expect that explor-
ing the effects of an increase in individual gene copy number will identify novel mech-
anisms for maintaining cell homeostasis. 
 
1.4 Protein-level dosage compensation is one mechanism for buffering against ge-
netic perturbations 
Global analyses of cell robustness against gene overexpression have revealed that cells 
tend to be fragile upon an increase in the copy number of genes encoding subunits of 
multi-protein complexes [17,18]. This is analogous to a previous study that predicted 
deleterious effects caused by an imbalance in subunit stoichiometries in complexes [26]. 
Interestingly, studies on aneuploidy have demonstrated that the copy number of a subset 
of genes, enriched in subunit-encoding genes, correlates with mRNA levels but not di-
rectly with protein levels. This phenomenon is known as protein-level dosage compen-
sation, reported in yeast and mammalian cells [9,24,27], which is illustrated in Figure 
1.3. The first example of genes with protein-level dosage compensation may be tubulin 
genes in S. cerevisiae [28]. This study manipulated the copy number of alpha-tubulin 
genes TUB1 and TUB3 and beta-tubulin gene TUB2 and measured changes in the pro-
tein level for each gene in some different copy number conditions. The level of Tub1 
protein increased to only 119% and 150% of wild-type level in the extra TUB1 (carry-
ing an additional copy of TUB1) and TUB1+2 (carrying an additional copy of TUB1 and 
TUB2) strains, respectively. The level of Tub2 protein also increased to only 115% of 
wild-type level in the extra TUB1+2 strain, while it was 92% in the extra TUB1 strain. 
Additionally, the level of Tub3 protein decreased to 74% and 88% of wild-type level in 
the extra TUB1 and TUB1+2 strains, respectively. 
Recent study using ribosome profiling technique [29] has shown that transla-
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tional efficiency of genes encoding subunits in a complex corresponds to a stoichiome-
try of the subunits [30]. This phenomenon is called a proportional synthesis strategy and 
guarantees stoichiometry of almost all the 18 well-characterized complexes tested in 
this study, with a small number of exceptions synthesized in excess (Srp54 and Sec65 in 
the signal recognition particle). Protein-level dosage compensation is expected to reduce 
excess subunits and directly contribute to maintaining the subunit stoichiometry. Be-
cause stoichiometric imbalance is a consequence of proteome imbalance, dosage com-
pensation is believed to play an important role for circumventing the imbalance and 
confer robustness to cell systems. 
 
1.5 Aim and scope of this study 
In this study, I developed a screening system based on the gTOW technique for the fol-
lowing aims: (i) to systematically identify genes with dosage compensation upon an in-
crease in gene copy number, and (ii) to estimate how much of the genome is subjected 
to dosage compensation. Findings from this study suggest that the proportion of the 
dosage-compensated genes in the genome is approximately 10% and these genes may 
encode subunits of protein complexes. I also investigated the compensation mechanism 
by focusing not only on protein degradation but also on translational efficiency by using 
a ribosome profiling technique [29]. This study suggests that the robustness of gene ex-
pression reflects transient degradation, dynamic changes in protein lifetime, produced in 
response to environmental changes. Furthermore, this study provides insight into the 
mechanisms !for coping with the fluctuations in biological processes caused by gene 
copy number alterations. I believe that the effect of alterations in gene copy number is 
one of the fundamental issues in genetics. Similarly, studies on the mechanisms for 
buffering against genetic perturbations may lead to a deeper understanding of cell ho-
meostasis in the context of robustness. In particular, this study may be useful for study-
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ing the robust formation of protein complexes. I also believe that the approach based on 
the gTOW technique provides a quantitative measurement of robustness in cellular sys-
tems.  
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1.6 Figures 
 
 
 
Figure 1.1. Gene expression processes and various mechanisms for regulating gene 
expression levels. 
Gene expression is ultimately a process for producing functional proteins (left panel). 
Gene expression levels are regulated by various mechanisms at each step of gene ex-
pression, and some of them are listed in the right panel. 
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Figure 1.2. Schematic understanding of the relationship between gene expression 
and cell robustness. 
Because cells are exposed to environmental changes and biological processes are not 
deterministic, gene expression fluctuates not only in stress conditions but also in physi-
ological conditions. If such perturbed gene expression is not buffered, it may result in 
breakdown of cellular systems. On the other hand, if the perturbed gene expression is 
buffered, and optimized gene expression is maintained, it can achieve robustness in cel-
lular systems. Therefore, fluctuations and optimization of gene expression may be criti-
cal for cellular robustness. 
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Figure 1.3. Protein-level dosage compensation. 
Majority of the genome shows a proportional increase in mRNA and protein levels 
when their gene copy number increases, as shown in the left panel. On the other hand, a 
small subset of the genome is subjected to dosage compensation at the protein level, as 
shown in the right panel. 
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Chapter 2 
 
Screening system to identify the dosage-compensated genes 
 
2.1 Introduction 
The decoding of genetic information is achieved through irreversible processes from 
DNA to RNA to protein as stated in the central dogma of molecular biology [31]. The 
gene expression level at each step is generally in a linear relationship with gene copy 
number, namely an increase in gene copy number leads to a proportional increase in 
mRNA and corresponding protein levels. However, in the face of perturbations, this 
linear relationship should become nonlinear for maintaining cellular homeostasis. This 
prediction highlights the importance of studying the quantitative aspects of the central 
dogma in the context of robustness. For example, previous studies have demonstrated 
that a small subset of genome shows protein-level dosage compensation upon genetic 
perturbations. A remarkable study using aneuploid yeast cells has revealed that ap-
proximately 20% of the yeast genome is subjected to dosage compensation [19]. This 
study used haploid S. cerevisiae that contains 16 chromosomes and analyzed 13 out of 
16 disomic strains that carry each of the additional chromosomes. Although this analy-
sis provides a systematic understanding of dosage compensation, some hallmarks of 
aneuploidy have raised the need of identification of the dosage-compensated genes in 
normal physiological condition. In aneuploid cells, protein synthesis and degradation 
networks are perturbed by excess amount of proteins, and as a consequence of proteome 
imbalance, the cells are exposed to proteotoxic stress that causes cell fragility leading to 
growth impairment. Indeed, many of disomic strains are sensitive to inhibitors of pro-
tein synthesis cycloheximide (CHX), hygromycin, and rapamycin and to proteasome 
inhibitor MG-132 compared with wild-type cells [25]. Moreover, they are sensitive to 
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geldanamycin, an inhibitor of a molecular chaperone Hsp90, suggesting the effects of 
aneuploidy on protein folding and the broad impact of proteome imbalance caused by 
aneuploidy. Interestingly, a recent study has shown that the fragility of aneuploid cells 
is caused by many genes on single additional chromosomes but not by duplicated dos-
age-sensitive genes that were identified by the gTOW analysis [23]. As described above, 
the genome-wide gTOW analysis has revealed that yeast cells grow robustly upon an 
individual increase in the copy number of approximately 98% of the yeast genome. 
Therefore, I developed an experimental setup based on the gTOW technique for 
screening of genes with protein-level dosage compensation in order to ask how much of 
the yeast genome is compensated.  
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2.2 Materials and Methods 
2.2.1 Strains 
The yeast strain BY4741 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0) [32] was used for the 
screening. Nucleotide sequence encoding the tandem affinity purification (TAP) (the 
detail components of the TAP tag is shown in Figure 2.1) or green fluorescence protein 
(GFP) tags were integrated into the 3´-region of each gene [33]. 
 
2.2.2 Plasmids 
A target gene with native regulatory regions, including promoter and 5´ and 3´ untrans-
lated regions, is cloned into a multicopy plasmid, pTOWug2-836 or pTOW40836 [18]. 
As shown in Figure 2.2, these plasmids contain leu2-d and URA3 genes as selective 
markers, so that yeast cells carrying this plasmid can be selected on synthetic complete 
medium lacking uracil (SC–Ura) or one lacking leucine and uracil (SC–Leu–Ura) me-
dia. 
 
2.2.3 Transformation of yeast cells 
Yeast strains were transformed by the lithium acetate method as described previously 
[34] with modifications. Yeast cells grown in YPD medium were harvested at log-phase 
and washed with sterile water. The cells were treated with 1 M lithium acetate at room 
temperature for 4 min, and then, sonicated salmon sperm DNA, plasmid, and 50% pol-
yethylene glycol were added to the cells. After mixing them, the mixture was incubated 
at room temperature for 30 min and 42 °C for 20 min, and then the cells were plated on 
SC–Ura plate and grown at 30 °C for a couple of days. The transformants were grown 
with shaking at 30 °C in SC–Ura or SC–Leu–Ura media. 
 
2.2.4 Western blot analysis 
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Yeast cells were grown in 2 mL of the appropriate medium and subcultured in 3 mL of 
fresh medium. The optical density at 600 nm (OD600) was measured and 2 OD600 units 
were harvested at log-phase. The cells were treated with 1 mL of 0.2 N NaOH for 5 min 
at room temperature and then were suspended in 2× NuPAGE LDS Sample Buffer 
(Invitrogen) and heated at 70 °C for 10 min. The supernatant corresponding to 0.5 OD600 
units was labeled with EzLabel FluoroNeo (ATTO) and subjected to SDS-PAGE, fol-
lowed by Western blotting with PAP (Sigma-Aldrich) (1:2000) or an anti-GFP antibody 
(Roche) (1:1000) and peroxidase-conjugated secondary antibody (Nichirei Biosciences) 
(1:1000). NuPAGE 4%–12% Bis-Tris Gel (Invitrogen) and iBlot Transfer Stack PVDF 
membrane (Invitrogen) were used for SDS-PAGE and Western blotting, respectively. 
Chemiluminescence was induced by SuperSignal West Femto Maximum Sensitivity 
Substrate (Thermo Scientific) and detected using LAS-4000 image analyzer (Fujifilm) 
and ImageQuant LAS 4000 (GE Healthcare). The band intensity was quantified using 
ImageQuant TL (GE Healthcare), and the fold change of protein levels was calculated 
with a previously described method [35]. 
 
2.2.5 Analysis of mRNA expression levels 
Yeast cells grown in the appropriate medium were harvested at log-phase and subse-
quently total RNA was extracted using the hot phenol method [36]. Contaminating ge-
nomic DNA was removed and reverse transcription was carried out with PrimeScript 
RT reagent Kit with gDNA Eraser (TaKaRa) according to the manufacturer’s instruc-
tions. The generated cDNA was amplified by real-time quantitative PCR with Light-
cycler 480 using SYBR Green I Master. Quantification of TAP tag and ACT1 mRNA 
expression was performed with the following primers to amplify TAP-tag and ACT1 
gene on the chromosome: TAP-tag-forward (5´-AATTTCATAGCCGTCTCAGCA-3´); 
TAP-tag-reverse (5´-CTCGCTAGCAGTAGTTGGAATATCA-3´); ACT1-forward 
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(5´-TGCAAACCGCTGCTCAA-3´); and ACT1-reverse 
(5´-TCCTTACGGACATCGACATCA-3´). The fold change of mRNA levels was cal-
culated as previously described [35]. 
 
2.2.6 Measurement of gene copy number 
The copy number of each gene was measured using the gTOW technique, as described 
previously [18]. Briefly, single colonies of yeast cells carrying pTOW plasmids were 
cultivated in a 96-well plate containing 200 µL of SC–Ura medium for 4 days at 30 °C, 
and then, 5 µL of the culture was inoculated into 200 µL of fresh SC–Ura medium. Af-
ter culturing for 50 h at 30 °C, the cells were harvested by filtration followed by DNA 
extraction with zymolyase treatment. The extracts were subjected to real-time quantita-
tive PCR with Lightcycler 480 (Roche) using SYBR Green I Master (Roche) to quanti-
fy the expression of LEU3 from the chromosome and leu2d gene from pTOW plasmids. 
The resulting copy number of the pTOW plasmid carrying each target gene was calcu-
lated according to the method described previously [21].  
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2.3 Results 
2.3.1 Identification of the dosage-compensated genes 
To identify genes with dosage compensation, I developed a screening method as shown 
in Figure 2.3A. The key idea of this method is to determine the protein level expressed 
from a single copy of a target gene when its copy number is increased. I monitored the 
level of each target protein labeled with the TAP tag expressed from the genomic locus 
when the copy number of the same target gene without the TAP tag is increased by a 
multicopy plasmid (Figure 2.3A, middle and right panels). If the expression level of the 
TAP-tagged protein is reduced in this situation, I consider that the target gene is sub-
jected to dosage compensation (Figure 2.3A, right panel), since the compensation 
mechanism should not distinguish the TAP-tagged endogenous protein from the 
non-tagged exogenous protein. Here, I call the condition where the target protein is ex-
pressed from the single genomic copy “Single” (Figure 2.3A, left panel) and the condi-
tion where the target protein is expressed from the genomic copy and the multicopy 
plasmid “Multi” (Figure 2.3A, middle and right panels). I used a series of strains in 
which the TAP tag is integrated into the 3´-region of each gene [33], and a plasmid col-
lection in which each target gene with native regulatory regions, including promoter and 
5´ and 3´ untranslated regions, is cloned into a multicopy plasmid, pTOWug2-836 [18]. 
I examined 54 genes on chromosome I whose TAP-tagged strains were 
available as representatives of the yeast genome (Table 2.1, Figure 2.4). By this screen, 
I identified five genes (RBG1, MTW1, POP5, SAW1, and ERP2) whose protein expres-
sion was reduced when their copy numbers were increased (Figure 2.3B). I did not de-
tect off-target effects of an increase in gene copy number by the gTOW technique: the 
total cellular protein level measured in the total cell lysate did not differ in the Single 
and Multi conditions. An example of this observation is shown in Figure 2.5A and 2.5C. 
Quantification of fold change of the protein levels was carried out as shown in Figure 
 23 
2.5. The protein levels of the dosage-compensated genes were 0.2–0.6-fold (Figure 
2.3C), when their copy numbers were 15–27 copies (Figure 2.6). I tested the linearity 
and accuracy of the Western blot analysis by performing the same analysis using 
two-fold serially diluted cell lysate (dilution range 1.2 to 0.075 OD600 units of cells). 
The signal intensities of a 50-kDa protein, corresponding to enolase, detected by 
SDS-PAGE were in a linear relationship with the amount of cell lysate (Figure 2.5A 
and 2.5C), as well as those of Rbg1-TAP detected by Western blot (Figure 2.5B and 
2.5D). I also calculated the fold change as shown in Figure 2.5E and observed dosage 
compensation in all dilution series (Figure 2.5F). The average of the fold changes in the 
dilution series and the original data shown in Figure 2.3C was very similar (0.46 and 
0.52, respectively). Therefore, I conclude that the quantification had been performed in 
a linear and accurate manner. Dosage compensations were performed by 
post-transcriptional regulation because mRNA levels from the endogenous locus did not 
change even when the copy numbers were increased (Figure 2.3D). Thus, I identified 
five genes with dosage compensation via post-transcriptional mechanisms. 
 
2.3.2 Observation of dosage compensation in the analysis of endogenous and exog-
enous protein levels 
To verify the experimental setup for measuring only the endogenous protein levels, I 
measured the level of a target protein expressed from both the genome and plasmid. The 
experimental setup is the same with that used for the analysis of endogenous protein 
except that the plasmid encodes each of the TAP-tagged target proteins (Figure 2.7). I 
measured the total TAP-tagged protein levels (Figure 2.7B and 2.7C) and the plasmid 
copy numbers (Figure 2.7D) and calculated the fold change of the protein levels per 
gene copy (Figure 2.7E). This analysis showed dosage compensation of all the five 
genes identified by the chromosome I screen when considering both endogenous and 
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exogenous protein levels (Figure 2.7F). The fold change values were very similar with 
those calculated from the endogenous protein levels. Thus, I conclude that the experi-
mental setup shown in Figure 2.3A, whereby I detect the TAP-tagged protein expressed 
from the genomic locus, can capture dosage compensation. 
 
2.3.3 Observation of dosage compensation using the GFP tag 
I further verified the experimental setup using GFP tag in order to assess the dependen-
cy of dosage compensation on the TAP tag. I used the yeast strains in which the GFP 
tag is integrated into the 3´-region of each target gene and measured the expression lev-
els of GFP-tagged target proteins upon an increase in gene copy number. Western blot 
analysis for the dosage-compensated proteins Rbg1 and Mtw1 and the uncompensated 
protein Pop8 showed reduced levels of Rbg1 and Mtw1 but not Pop8 in the Multi con-
dition (Figure 2.8). Because the similar degree of the compensation was observed be-
tween the analyses using the TAP and GFP tags, dosage compensation is not a 
TAP-tag-mediated phenomenon. 
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2.4 Discussion 
I developed a screening method based on the gTOW technique in order to systematical-
ly identify the dosage-compensated genes and estimate how much of the genome is 
subjected to the compensation (Figure 2.3A). The screen of chromosome I showed that 
5 out of 54 genes are regulated by the compensation (Figure 2.3B), which estimates that 
dosage compensation confers robustness to 10% of the genome for buffering perturbed 
gene expression. As described above, in disomic yeast strains, 20% of the genome is 
subjected to the compensation at the protein level [19]. This suggests that there are dif-
ferent mechanisms by which cells reduce the level of target proteins for dosage com-
pensation. Indeed, Mtw1, the dosage-compensated proteins identified in this study, is 
not compensated in aneuploid cells [19]. Previous studies have demonstrated that aneu-
ploidy-induced proteotoxic stress causes cell fragility leading to growth impairment. 
Thus I expect that there are different rules for determining the target of dosage com-
pensation in the aneuploid condition and that the difference is produced in response to 
aneuploidy-specific physiological conditions associated with proteotoxicity [13]. I also 
expect that the gTOW technique allows sensitive detection of the dosage-compensated 
genes by a much higher increase in copy number of a single target gene than duplication 
of the same gene in disomic cells. 
I verified the screening method for identification of the dosage-compensated 
proteins by the following two experiments: (i) measuring the total protein levels from 
the genome and plasmid, measuring the copy number of the plasmid, and calculating 
protein level per gene copy, and (ii) measuring endogenous protein level with the GFP 
tag for validation of the results obtained using the TAP tag. First, I analyzed the total 
levels of a target protein expressed from both a genomic locus and multicopy plasmids. 
I used a multicopy plasmid encoding each of the TAP-tagged version of the five pro-
teins that had been identified by the screen of chromosome I. I performed Western blot 
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analysis for detecting the protein levels and the gTOW analysis for measuring plasmid 
copy number and calculated the fold change of the protein levels per gene copy. This 
analysis showed that the protein levels per gene copy were similar with the endogenous 
protein levels. Therefore, I conclude that dosage compensation was observed when con-
sidering the total protein levels and was captured by measuring the level of endogenous 
protein. Second, I verified dosage compensation of a subset of candidates using the GFP 
tag in order to examine the possibility that dosage compensation was observed due to 
the TAP tag. I used the same experimental setup with the analysis of endogenous 
TAP-tagged proteins (Figure 2.3A) and measured the levels of the dosage-compensated 
proteins Rbg1 and Mtw1 and the uncompensated protein Pop8. This experiments 
showed dosage compensation of Rbg1 and Mtw1 but not Pop8. Because this result is 
consistent with the observations obtained with the TAP tag, I conclude that dosage 
compensation is not a TAP-tag-mediated phenomenon. 
Because a plasmid collection for the genome-wide gTOW analysis was pre-
pared in a previous study [18], I used it and screened more than 50% (54 out of 96) of 
genes on S. cerevisiae chromosome I. Genome-wide collections of TAP- or GFP-tagged 
yeast strains are also available [33,37], so that the method developed in this study can 
be applied to a genome-wide screen. I believe that this challenge leads to a deeper un-
derstanding of robustness in gene expression and cellular systems. However, if trying to 
carry out this challenge, some modifications for the screening method are necessary in 
order to make it high-throughput because Western blotting for TAP-tagged proteins 
performed in the screen is low-throughput. Here, I propose three modifications for a 
better experimental-setup applicable for the genome-wide analysis of the dos-
age-compensated genes in S. cerevisiae. As a premise of the three approaches, it is nec-
essary to prepare the GFP-tagged strain harboring pTOW40836 (Figure 2.2) or the same 
plasmid carrying a gene of interest. I call these strains “multicopy GFP-strains”. First, 
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measuring fluorescence intensity of GFP in the multicopy GFP-strains by flow cytome-
ter. This enables rapid screening and provides distribution of the number of GFP posi-
tive cells, so that it is possible to check whether there is a heterogeneous population. If 
this analysis would observe a heterogeneous population, including cells with high and 
low GFP intensities (low and high degrees of dosage compensation, respectively), and 
the gTOW analysis would show lower and higher gene copy numbers in cells with high 
and low GFP intensities, it allows us to expect that the degree of dosage compensation 
relates to gene copy number. Second, measuring GFP intensity in the multicopy 
GFP-strains by a plate reader, which also enables rapid screening. Because this analysis 
provides time course data, if changes in GFP intensity during dosage compensation are 
clear, it allows us to expect that there is a mechanism affecting dosage compensation 
level. Third, fluorescence microscopic analysis of the multicopy GFP-strains using the 
CellProfiler program [38]. The CellProfiler is able to automatically quantify GFP inten-
sity in each cell. A recent study quantified the abundance and localization of yeast pro-
teome by fluorescence microscopic analysis including quantification using the CellPro-
filer [39]. This study also used machine learning technique in order to quantify the 
abundance of proteins localized to each organelle. If applying this approach to the 
screen of the dosage-compensated genes, it may be possible to investigate the relation-
ship between dosage compensation and the abundance of correctly localized protein. If 
protein localization would not differ during dosage compensation, it suggests that dos-
age compensation decreases the amount of protein but keeps the amount of functional 
protein constant. As described here, all three approaches have a potential to provide new 
frontiers for the research on dosage compensation. 
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2.5 Table 
 
Table 2.1. 54 genes tested in the screen of chromosome I. 
 
  
# Gene # Gene
1 BDH2 28 FUN26
2 BDH1 29 CCR4
3 ECM1 30 FUN30
4 CNE1 31 PSK1
5 GPB2 32 TPD3
6 PEX22 33 NTG1
7 ACS1 34 CYS3
8 FLC2 35 SWC3
9 OAF1 36 MDM10
10 AIM2 37 SPO7
11 AIM1 38 FUN14
12 YAL044W-A 39 ERP2
13 GCV3 40 SSA1
14 PTA1 41 VPS8
15 CDC24 42 TFC3
16 CYC3 43 NUP60
17 CDC19 44 ERP1
18 RBG1 45 SWD1
19 FUN12 46 RFA1
20 MTW1 47 YAR009C
21 POP5 48 BUD14
22 GIP4 49 ADE1
23 MYO4 50 CDC15
24 SAW1 51 YAR028W
25 DRS2 52 PRM9
26 LTE1 53 YAR064W
27 PMT2 54 PHO11
 29 
2.6 Figures 
 
 
 
Figure 2.1. Overview of the detection of TAP-tagged protein by Western blotting 
with PAP. 
Three components of the TAP tag: calmodulin binding peptide, tobacco etch virus 
(TEV) protease cleavage site, and Protein A. Peroxidase anti-peroxidase soluble com-
plex (PAP) includes HRP and IgG, which binds to Protein A. HRP reacts with the sub-
strate (the product is called ECL), and this enzymatic reaction induces chemical lumi-
nescence, so that TAP-tagged protein is detected by Western blotting with PAP. 
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Figure 2.2. Maps of the multi-copy plasmid pTOWug2-836 and pTOW40836. 
(A) The pTOWug2-836 plasmid contains URA3 and leu2-d genes, which are used not 
only for selective markers but also for increasing the copy number of a target gene in 
the gTOW experiment as described above. 
(B) The pTOW40836 plasmid is the same as pTOWug2-836 except that EGFP gene is 
not integrated into the 3´-end of URA3. 
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Figure 2.3. Identification of genes with dosage compensation. 
(A) Schematic overview of the screening. Left panel (Single): TAP-tagged strain trans-
formed with the empty vector. The native level of the target protein expressed only from 
the genomic copy is detected by Western blotting with PAP. Middle and right panels 
(Multi): TAP-tagged strain transformed with the multicopy plasmid carrying the target 
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gene without the TAP tag. If the level of TAP-tagged target protein is not reduced 
compared with that in the Single condition (middle panel), the target protein (Protein A) 
is not subjected to dosage compensation (uncompensated). If the level of TAP-tagged 
target protein is reduced compared with that in the Single condition (right panel), the 
target protein (Protein B) is subjected to dosage compensation (compensated). The cells 
carrying multicopy plasmid were grown in synthetic complete medium lacking uracil 
(SC–Ura). 
(B) Western blots of proteins whose expressions are reduced upon an increase in their 
gene copy numbers. Cne1 is an example of the uncompensated proteins. 
(C, D) Quantification of protein (C) and mRNA (D) expression levels of the identified 
genes. The mRNA level of each TAP-tagged target gene was measured by reverse tran-
scriptase-PCR and normalized to ACT1 mRNA levels. The average fold changes ± 
standard deviation (s.d.) from three biological replicates were calculated relative to the 
Single condition. Dashed line denotes the same expression level between the Multi and 
Single conditions. 
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Figure 2.4. Full results of the screening of the dosage-compensated genes. 
More than 50% (54 out of 96) of genes on chromosome I were screened. Each rectangle 
includes the systematic name, standard name, and the result of Western blot (the Multi 
and Single conditions on the left and right, respectively). Rectangles with a pink line 
denote the dosage-compensated genes. A chromosome map was adopted and modified 
from the Saccharomyces Genome Database website [40]. 
  
 36 
 
 
Figure 2.5. The linearity and accuracy of the protein quantification. 
(A) SDS-PAGE of two-fold serially diluted cell lysate. The lysate prepared from cells 
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cultured in the Single or Multi conditions were loaded on the same gel. A red rectangle 
marks the area of a 50-kDa protein, corresponding to enolase, used as a loading control 
of Western blot analysis. 
(B) Western blot of two-fold serially diluted cell lysate. The gel shown in Figure 2.5A 
was blotted onto PVDF membrane and Rbg1-TAP in the total lysate was detected by 
Western blot with PAP. A red rectangle marks the area of Rbg1-TAP. 
(C) The area of a 50-kDa protein cropped from the gel shown in Figure 2.5A (upper 
panel). The signal intensity of each band was measured after background subtraction, 
and the net intensity was plotted on the y-axis (lower panel). The amount of lysate had a 
correlation coefficient (R2) of 0.99 with the net intensity in both the Single and Multi 
conditions. 
(D) The area of Rbg1-TAP cropped from the membrane shown in Figure 2.5B (upper 
panel). The net intensity of each band was measured after background subtraction, and 
the net intensity was plotted on the y-axis (lower panel). The amount of lysate had a 
correlation with the net intensity of Rbg1-TAP in the Single and Multi conditions (R2 = 
0.97 and 0.99, respectively). 
(E) Quantification of fold change in Rbg1-TAP level between the Single and Multi 
conditions. The case of analyzing 0.6 OD600 units of cells is shown as an example. The 
net intensities of a 50-kDa protein and Rbg1-TAP from the Multi condition were divid-
ed by those from the Single condition to calculate the PAGE fold change and the WB 
fold change, respectively. Protein fold change was calculated by dividing the WB fold 
change by the PAGE fold change. 
(F) The protein fold change calculated from the analysis of each OD600 units of cells. 
Only non-saturated signals were used for all the quantification analysis. Dashed line 
denotes the same expression level between the Multi and Single conditions. For com-
parison, the result of the Western blot analysis using 0.5 OD600 units of cells, the same 
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data shown in Figure 2.3C, is shown. 
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Figure 2.6. Gene copy number during dosage compensation. 
Bar graph indicates the copy numbers of pTOWug2-836 (Vector) and the plasmid car-
rying each of the indicated genes in each TAP-tagged strain. The copy numbers were 
measured by the gTOW technique. The average copy numbers ± s.d. were calculated 
from four biological replicates.  
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Figure 2.7. Observation of dosage compensation in the analysis of endogenous and 
exogenous protein levels. 
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(A) Schematic overview of the analysis of endogenous and exogenous proteins. Left 
panel (Single): TAP-tagged strain transformed with the empty vector. The native level 
of the target protein expressed only from the genomic copy is detected by Western blot-
ting with PAP. Middle and right panels (Multi): TAP-tagged strain transformed with the 
multicopy plasmid carrying the target gene with the TAP tag. If the level of the 
TAP-tagged target protein per gene copy is not reduced compared with that in the Sin-
gle condition (middle panel), the target protein is not subjected to dosage compensation. 
On the other hand, if the level of the TAP-tagged target protein per gene copy is re-
duced (right panel), the target protein is subjected to dosage compensation. The cells 
carrying a multicopy plasmid were grown in SC–Ura medium. 
(B) Western blot with PAP for the indicated TAP-tagged proteins expressed from the 
genome and the multicopy plasmid. 
(C) Quantification of the expression levels of the identified proteins. The average fold 
changes ± s.d. from three biological replicates were calculated relative to the Single 
condition. Protein levels at the same dilution in the Multi and Single conditions were 
used for the quantification. 
(D) Bar graph indicates the copy number of pTOW40836 carrying each of the indicated 
genes with the TAP tag. The copy numbers were measured by the gTOW technique. 
The average copy numbers ± s.d. were calculated from more than three biological rep-
licates. 
(E) Quantification method of protein fold change per gene copy. The case of analyzing 
Rbg1 level is shown as an example. The fold change in Rbg1-TAP level between the 
Single and Multi conditions was divided by the RBG1 copy number. 
(F) Bar graph indicates the fold changes of the indicated proteins per gene copy. The 
average fold changes ± s.d. were calculated from three biological replicates. Dashed line 
denotes the same expression level between the Multi and Single conditions. For com-
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parison, the result of Western blot analysis detecting the only endogenous target protein, 
the same data shown in Figure 2.3C, is shown. 
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Figure 2.8. Observation of dosage compensation using the GFP tag. 
(A) Western blot of the dosage-compensated proteins identified from the screen of 
chromosome I. GFP-tagged target proteins expressed from the genomic regions were 
detected with an anti-GFP antibody. Pop8 is an example of the uncompensated proteins. 
(B) Quantification of the expression levels of the indicated proteins. The average fold 
changes ± s.d. relative to the Single condition were calculated from three biological rep-
licates. Dashed line denotes the same expression level between the Multi and Single 
conditions. For comparison, the results obtained using the TAP tag, the same data 
shown in Figure 2.3C and 4.1B, are shown. 
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Chapter 3 
 
Mechanism of dosage compensation 
 
3.1 Introduction 
Since mRNA levels of the dosage-compensated genes did not differ upon an increase in 
their copy number, there are two possible mechanisms that underlie protein-level dos-
age compensation: translation- and proteolysis-mediated compensation (Figure 3.1). 
Thus, I examined the contributions of two major degradation pathways the ubiquitin–
proteasome and the autophagy–lysosome systems to dosage compensation using mutant 
strains of each pathway. I also examined the involvement of reduced translational effi-
ciency in the compensation mechanisms using the ribosome profiling technique. 
 The ubiquitin–proteasome system is a major degradation pathway conserved 
in a wide range of eukaryotic organisms, which selectively degrades ubiquitinated pro-
teins as substrates. The 26S ubiquitin-dependent proteasome is a macromolecular com-
plex and consists of one or two 19S regulatory particles and one 20S catalytic particle. 
Ubiquitin conjugated to a target protein is recognized by the 19S particles, and the 
ubiquitinated protein is unfolded and translocated into the 20S particle. Therefore, 
ubiquitination of the dosage-compensated protein is a direct evidence for the compensa-
tion by the ubiquitin–proteasome system. I used a mutant strain of the 19S particles to 
examine whether the degree of the compensation decreased in this mutant compared 
with that in wild-type cells and that ubiquitinated form of the dosage-compensated pro-
tein is accumulated in the 19S particles mutant. 
The autophagy–lysosome system is one of the major pathways of protein 
degradation and is widely conserved in eukaryotic cells. This pathway is activated by 
various stress including starvation and is performed in the following three steps: (i) 
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formation of a characteristic intracellular structure autophagosome that surrounds a por-
tion of cytosol, (ii) formation of autolysosome that is a fusion of the autophagosome 
and lysosome, and (iii) degradation of proteins in the autolysosome by many types of 
protease contained in lysosome. Because autophagy is performed in a non-selective 
manner and degrades a large amount of proteins at one time, autophagy is generally 
known as a bulk degradation system. Recent studies have shown some examples that 
autophagy selectively degrades specific organelle (e.g., nucleophagy, mitophagy, 
ER-phagy, pexophagy [41]) and proteins (e.g., Cue5-mediated degradation of ubiquiti-
bated proteins [42], ribophagy for ribosome-specific degradation [43]). Activation of 
autophagy has been shown in aneuploid mammalian cells [44,45], which seems to con-
fer tolerance to proteotoxicity due to aneuploidy-induced proteome imbalance. To veri-
fy autophagy-mediated dosage compensation, I used two autophagy mutants, atg5∆ and 
pep4∆ strains. Atg5 and Pep4 proteins play important roles in autophagosome formation 
and protein degradation in the autolysosome, respectively. The use of these mutants al-
lowed examination of the contribution of each specific step in the progression of au-
tophagy to dosage compensation. If autophagy is involved in the compensation mecha-
nisms, the degree of the compensation should decrease. 
 In some disomic yeast strains, translational efficiency of the doubled number 
of genes is not altered [19,46]. This indicates that translational efficiency is not per-
turbed by an increased burden on cellular systems for protein homeostasis including the 
translation, folding, and degradation machineries. There may be no evidence of transla-
tion-mediated dosage compensation; however, in disomic yeast cells, there are the dos-
age-compensated proteins whose compensation levels are high even when treated with 
proteasome inhibitor MG-132 and autophagy inhibitor chloroquine [19]. Therefore, an 
investigation of the involvement of translational control in the compensation mecha-
nisms is still needed in order to explain the reduction of protein level under genetic per-
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turbations and better understand dosage compensation. 
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3.2 Materials and Methods 
3.2.1 Strains 
The W303-1B (MATα ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100) [47] and 
CMY765 (MATα cim5-1 ura3-52 leu2∆1 his3∆200) [48] strains were used for the 
analysis of the ubiquitin–proteasome system. The yeast strains BY4741, atg5∆ (MATa 
atg5∆::KanMX his3∆1 leu2∆0 met15∆0 ura3∆0), and pep4∆ (MATa pep4∆::KanMX 
his3∆1 leu2∆0 met15∆0 ura3∆0) were used for the analysis of the autophagy–lysosome 
system. BY4741 was used for ribosome profiling. These strains were transformed with 
empty vector pTOWug2-836 or the same vector carrying the gene of interest. Trans-
formation of the yeast strains was performed by the lithium acetate method as described 
above. 
 
3.2.2 Growth media and conditions 
The transformants were grown at 30 °C except those that CMY765 was used as a host 
strain. CMY765 is a temperature-sensitive mutant, and 24 °C and 30 °C are permissive 
and semi-permissive temperature for its growth, respectively. The transformed cells of 
CMY765 strain were grown at 24 °C on SC–Ura plate, and then, the cells were inocu-
lated in SC–Ura medium and grown at 30 °C. 
 
3.2.3 TAP pull-down and Western blot analysis of ubiquitinated proteins 
TAP-tagged strains carrying pTOW plasmid were grown at 30 °C in 100 mL of SC–Ura 
medium. The whole cells were harvested at log-phase and lysed with glass beads in 750 
µL of lysis buffer [20 mM HEPES, 2 mM EDTA, 100 mM NaCl, 20% glycerol, 0.05% 
IGEPAL CA-630 (Sigma-Aldrich), Protease Inhibitor Cocktail, EDTA-Free (Thermo 
Scientific)] with 20 mM N-ethylmaleimide. The supernatant was immunoprecipitated 
using Dynabeads coated with pan-mouse IgG (Life Technologies), as described previ-
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ously [49]. In short, the supernatant was incubated with 40 µL of Dynabeads in a 
Thermomixer Comfort (Eppendorf) at 21 °C for 2 h with shaking at 1300 rpm. The 
Dynabeads were washed one time with the lysis buffer and three times with the lysis 
buffer containing 150 mM NaCl and suspended in 16 µL of AcTEV buffer (Invitrogen) 
containing 1 mM DTT. Before TEV cleavage, for Western blot analysis of TAP-tagged 
protein, 2 µL of the suspension was removed and suspended in 10 µL of 2× NuPAGE 
LDS Sample Buffer and heated at 65 °C for 20 min. The remaining Dynabeads were 
then treated with 1 µL (10 units) of AcTEV protease (Invitrogen) in a Thermomixer 
Comfort at 4 °C for 16 h with shaking at 1300 rpm. The supernatant was subjected to 
Western blotting with polyclonal rabbit anti-ubiquitin antibody (DAKO) (1:500) as 
primary antibody and peroxidase-conjugated secondary antibody (Nichirei Biosciences). 
After TEV cleavage, the Dynabeads were suspended in 14 µL of 2× NuPAGE LDS 
Sample Buffer and heated at 65 °C for 20 min, and 2 µL of the extracts were mixed 
with 8 µL of 2× NuPAGE LDS Sample Buffer and analyzed by Western blotting with 
PAP. Detection of chemiluminescence was performed as described above. 
 
3.2.4 Ribosome profiling 
Yeast cells BY4741 expressing POP5-TAP from a single genomic locus and carrying 
pTOWug2-836 or pTOWug2-POP5 were grown in 150 mL of SC–Ura at 30 °C with 
vigorous shaking. These cells were grown from an initial OD600 of approximately 0.2 to 
OD600 around 0.7, and the cells were then harvested by vacuum filtration. The cell pellet 
was immediately immersed in a 50 mL conical tube filled with liquid nitrogen and 2 mL 
of lysis buffer [10 mM Tris-HCl (pH 7.0), 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 
mM MgCl2, 1 mM DTT, 1% Triton X-100, 200 µg/mL CHX, 25 U/mL Turbo DNase 
(Invitrogen)] was dripped into the tube. 
Extracts were prepared as previously described [29], except that the frozen 
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cells were pulverized with a mixer mill at 30 Hz. The total amount of RNA in the ex-
tracts was quantified using RiboGreen (Invitrogen), and then, 50 µg of total RNA was 
diluted to 300 µL with the lysis buffer. The sample was subjected to preparation of ri-
bosome footprints according to a previously described method [50]. Briefly, total RNA 
was treated with RNase I (Epicentre), and then the ribosomal pellet was collected by 
sucrose cushion centrifugation. RNA was recovered from the pellet with TRIzol (Life 
Technologies) and purified with Direct-zol RNA MiniPrep (Zymo), followed by iso-
propanol precipitation. The resulting RNA was subjected to gel electrophoresis, and 
then, the 26–34-nucleotides regions were excised. The size-selected fragments were 
subjected to dephosphorylation with T4 PNK (New England Biolabs) and linker liga-
tion with T4 Rnl2 (New England Biolabs). Ribosomal RNA (rRNA) was depleted from 
the sample using Ribo-Zero Magnetic Gold Kit for yeast (Epicentre). Reverse transcrip-
tion was carried out with Protoscript II (New England Biolabs) on the rRNA-depleted 
sample. The reverse transcription product was then separated by gel electrophoresis, and 
the full-length product was excised. 
The size-selected product was circularized with CircLigaseII (Epicentre). The 
circularized DNA was amplified by 6, 8, 10, 12, and 14 cycles of PCR with Phusion 
polymerase (New England Biolabs). The PCR products were loaded on gel, and the 
products of eight cycles were excised. The quality of the PCR product was assessed us-
ing Agilent 2200 TapeStation (Agilent Technologies). Deep sequencing (50 bp, sin-
gle-end reads) was then performed on the Illumina HiSeq 4000 (Illumina). RNA se-
quencing (RNA-seq) libraries were generated using TruSeq Standard Total RNA Li-
brary Prep Kit (Illumina) from total RNA prepared as described above, and then, deep 
sequencing was performed in the same run with ribosome footprint sequencing. 
The profiling analysis was performed according to the method previously de-
scribed [50,51] with modifications for the analysis of budding yeast profiling. In short, 
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rRNA sequences were aligned to a set of budding yeast rRNA sequences, and then, 
non-rRNA reads were aligned to the budding yeast transcriptome. A-site offsets of ri-
bosome footprints and mRNA fragments were estimated from 13 to 17 nucleotides for 
each read length of 26–30 nucleotides and 15 nucleotides for 22–51 nucleotides, respec-
tively. The mapped reads excluding the first 15 codons and last 5 codons were counted 
based on the A-site offsets. DESeq was used to calculate fold change of RNA expres-
sion and translational efficiency [52]. Ribosome profiling and RNA-seq data analysis 
did not distinguish the reads from endogenous or exogenous POP5 copies. 
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3.3 Results 
3.3.1 Major contribution of the ubiquitin–proteasome system to dosage compensa-
tion 
Given that dosage compensation is performed by post-transcriptional mechanisms (Fig-
ure 2.3D), the deceleration of protein synthesis and/or the acceleration of protein deg-
radation should be the mechanisms of dosage compensation (Figure 3.1). I first exam-
ined the contribution of protein degradation by focusing on the ubiquitin–proteasome 
system, a major selective degradation pathway. I used CMY765 (cim5-1) strain as a 
proteasome-defective mutant [48] to test whether the compensation is not observed in 
this mutant. As shown in Figure 3.2A and 3.2B, the dosage compensations of Rbg1, 
Mtw1, and Erp2 were significantly weaker in cim5-1 than in wild-type strain W303-1B 
(CIM5). The compensations of Pop5 and Saw1 also tended to be weaker in cim5-1 mu-
tant, although the difference was not statistically significant (Figure 3.3). The mRNA 
levels of these genes in cim5-1 and CIM5 cells did not differ (Figure 3.4). 
To further verify the participation of the ubiquitin–proteasome system in 
dosage compensation, I examined the ubiquitination of the compensated proteins. The 
TAP-tagged proteins were immunoprecipitated with IgG-coated beads and cleaved with 
TEV protease, and the cleaved proteins were analyzed by Western blotting using an-
ti-ubiquitin antibody (Figure 3.2C). Because the expression levels of the dos-
age-compensated proteins and the pull-down efficiency were different among the sam-
ples (Figure 3.2D), I normalized the ubiquitination level by dividing it by loading 
amount of immunoprecipitated proteins as described in Figure 3.2E. I compared the 
amount of the TAP-tagged proteins captured on the beads before and after TEV cleav-
age, which reflects the amount of immunoprecipitates analyzed by Western blotting for 
ubiquitinated proteins. This analysis showed a tendency to accumulate the greater 
amount of ubiquitinated proteins in cim5-1 cells upon the Multi condition (Figure 3.2F). 
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These results strongly suggest that protein degradation by the ubiquitin–proteasome 
system is the main mechanism of dosage compensation. 
 
3.3.2 The autophagy–lysosome system is not responsible for dosage compensation 
Next, I examined protein levels of the dosage-compensated genes in atg5∆ or pep4∆ 
strains in which the TAP tag is integrated into the 3´-region of each target gene. PEP4 
encodes a protease contained in lysosomes, and a deletion mutant of this gene is often 
used as an autophagy-defective mutant as well as atg5∆ strain. I examined the levels of 
the five dosage-compensated proteins, identified by the screen of chromosome I, in the 
Multi and Single conditions by Western blot analysis with PAP. This analysis showed 
that for all genes tested, protein levels decreased in the Multi condition compared with 
those in the Single condition (Figure 3.5). In addition, the reduction of Rbg1 level was 
stronger in atg5∆ and pep4∆ strains than that in wild-type strain; fold changes are 0.41, 
0.31, and 0.70 in atg5∆, pep4∆, and wild-type strains, respectively. These results indi-
cate that dosage compensation was observed in autophagy mutants. Therefore, I con-
clude that the autophagy–lysosome system may not be involved in the compensation 
mechanisms. 
 
3.3.3 Translational efficiency of POP5 is not changed during dosage compensation 
I also examined the contribution of translational control to dosage compensation. A 
high compensation level of Pop5 in cim5-1 cells (Figure 3.2B) prompted me to measure 
the translational efficiency change upon an increase in POP5 copy number. I performed 
ribosome profiling and RNA-seq and measured translation rate comparing between the 
Single and Multi conditions of Pop5 gene copy number. While a high copy number of 
POP5 led to an increase in its mRNA expression (Figure 3.6A and 3.6C), the ribosome 
density per mRNA was not changed (Figure 3.6B and 3.6C). The RNA-seq analysis al-
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so indicates that an increase in POP5 copy number by the gTOW technique specifically 
increased its mRNA level and did not induce off-target effects on mRNA expression of 
the other genes. Therefore, I conclude that translational efficiency is not responsible for 
dosage compensation, at least in the case of Pop5. Residual proteasome activity in 
cim5-1 mutant or alternative systems may specifically degrade Pop5 protein upon an 
increase in its gene copy number. 
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3.4 Discussion 
Understanding the underlying mechanisms of dosage compensation does expand our 
understanding of cell robustness for buffering against genetic perturbations. I examined 
the involvement of the ubiquitin–proteasome system, the autophagy–lysosome system, 
and downregulation of translational efficiency in the compensation mechanisms. These 
analyses revealed that proteasomal degradation is the mechanism of dosage compensa-
tion (Figure 3.2). Although accumulation of ubiquitinated proteins has been found in 
disomic yeast strain [15], ubiquitination of the dosage-compensated proteins has not 
been shown. In this study, I obtained direct evidence for ubiquitination of the individual 
dosage-compensated proteins by performing immunoprecipitation of the dos-
age-compensated proteins (Figure 3.2C). On the other hand, the contribution of the au-
tophagy–lysosome system and translational control to the compensation was not obser-
ved in the analysis of autophagy mutants and wild-type cells carrying high copy num-
bers of Pop5 gene, respectively. Taken together, the ubiquitin–proteasome system may 
be the main mechanism of dosage compensation. For the further study, identification of 
the E3 ubiquitin ligase responsible for dosage compensation may provide a deeper un-
derstanding of upstream process of ubiquitin-dependent dosage compensation. Previous 
study suggests that Tom1 is one of the E3 ubiquitin ligases that contributes to cope with 
gene overexpression from the observation that tom1∆ strain is sensitive to overexpres-
sion of histone H3 (Hht2) compared with wild-type strain [53]. Because there are large 
numbers of the E3 ligases in S. cerevisiae, systematic identification is preferable for 
further analysis needed for bridging a gap between an increase in gene copy number and 
ubiquitination of the dosage-compensated proteins. 
Interestingly, in the analysis of autophagy, I observed higher reduction of 
Rbg1 and Pop5 levels in atg5∆ and pep4∆ strains than in wild-type strain. This might 
result from upregulation of proteasome activity induced by a defect in autophagy be-
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cause there is a crosstalk between proteasome and autophagy [54,55]. Indeed, higher 
proteasome activity was observed in autophagy mutants [56]. Since degradation by the 
26S proteasome may be the main mechanism of dosage compensation, this upregulation 
of proteasome activity may explain the lower levels of the dosage-compensated proteins 
in atg5∆ and pep4∆ strains. In other words, these data support that dosage compensa-
tion is performed through ubiquitin-dependent degradation. 
As described above, I obtained no evidence of the involvement of autophagy 
in dosage compensation. A contribution of autophagy to the compensation has been ex-
pected in mammalian aneuploid cells because higher expression of autophagy-related 
proteins were observed [27,44]; however, it has not been observed in aneuploid yeast 
cells. This observation is thought to reflect differences in cell systems between mamma-
lian and yeast cells. Further studies are needed to determine whether autophagy partici-
pates in dosage compensation and to elucidate the mechanisms behind that observation. 
This study shows no evidence for a direct effect of translational efficiency to 
the compensation of Pop5 protein (Figure 3.6B and 3.6C). This result supports the ro-
bust translational efficiency of duplicated genes in aneuploid yeast strains [19,46]. 
However, it should be noted that an increase in a single gene to approximately 20 copies 
does not result in a decrease in ribosome occupancy for its mRNAs (Figure 2.6, 3.6B, 
and 3.6C). I speculate that translational efficiency is not responsible for dosage com-
pensation and that translation is quite robust against genetic perturbations caused by an 
increase in gene copy number. 
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3.5 Figures 
 
 
 
 
Figure 3.1. Possible mechanisms of dosage compensation. 
C 
 57 
(A, B) The abundance of mRNA and protein in a cell is a result of a balance between 
their synthesis and degradation. If a target gene is not subjected to protein-level dosage 
compensation, an increase in gene copy number results in a linear increase in mRNA 
and protein levels. A deceleration of translation (A) and an acceleration of degradation 
(B) can explain a nonlinear relationship between gene copy number and protein level 
via dosage compensation. 
(C) Cells have two major protein degradation pathways, the ubiquitin–proteasome and 
the autophagy–lysosome systems, so that I examined the possibility of proteoly-
sis-mediated dosage compensation by analyzing the contribution of each pathway to 
dosage compensation. I also examined the involvement of the translational control in 
the compensation mechanism. 
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Figure 3.2. Major contribution of the ubiquitin–proteasome system to dosage 
compensation. 
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(A) Western blots showing the amount of the indicated proteins in CIM5 (W303-1B) 
and cim5-1 (CMY765) strains grown in SC–Ura medium. The TAP-tagged target pro-
teins expressed from the genomic regions were detected with PAP. 
(B) Quantification of the amount of the indicated proteins. The average fold changes ± 
s.d. from more than three biological replicates were calculated relative to the Single 
condition. Dashed line denotes the same expression level between the Multi and Single 
conditions. P values were determined by a one-tailed Mann Whitney U test (*P < 0.05). 
(C) Ubiquitination of the dosage-compensated proteins. The TAP-tagged proteins ex-
pressed in the indicated conditions were immunoprecipitated with IgG-coated beads and 
cleaved with TEV protease, followed by Western blotting with anti-ubiquitin antibody. 
The bracket indicates poly-ubiquitinated species. 
(D) Western blots of the dosage-compensated proteins captured on the beads. The 
TAP-tagged target proteins before and after TEV cleavage were detected with PAP. A 
combination of strain and condition of gene copy number in each lane is identical with 
Figure 3.2C. 
(E, F) Quantification of the levels of ubiquitinated proteins. Band intensity of ubiqui-
tinated proteins were normalized by dividing it by loading amount of the TAP-tagged 
proteins (E). Bar graph indicates the normalized ubiquitination level of each of the 
dosage-compensated proteins in CIM5 and cim5-1 cells under the Single and Multi 
conditions (F). 
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Figure 3.3. A tendency for reduced levels of dosage compensation in cim5-1 strain. 
Bar graph indicates the fold change of each target protein. All data points of Figure 
3.2B are shown. The fold change of Saw1 level in CIM5 strain of replicate #3 was al-
most zero. 
  
 61 
 
 
Figure 3.4. The mRNA levels of the dosage-compensated genes in cim5-1 strain. 
The TAP mRNA levels of the indicated genes in CIM5 (W303-1B) and cim5-1 
(CMY765) strains grown in SC–Ura medium. The mRNA levels were measured by re-
verse transcriptase-PCR and normalized to ACT1 mRNA levels. The average fold 
changes ± s.d. from three biological replicates were calculated relative to the Single 
condition. Dashed line denotes the same expression level between the Multi and Single 
conditions. 
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Figure 3.5. Dosage compensation is observed in autophagy mutants. 
Western blot analysis of the indicated proteins in atg5∆ and pep4∆ strains grown in SC–
Ura medium. The TAP-tagged target proteins expressed under the Single or Multi con-
ditions were detected with PAP. A 50-kDa protein on SDS-PAGE is shown as a loading 
control.  
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Figure 3.6. Translational efficiency of POP5 is not changed during dosage com-
pensation. 
(A, B) Scatter plots showing the changes in mRNA levels (A) and the translational effi-
ciency (B) of the genome in the Pop5-TAP strain carrying multicopy plasmid 
pTOWug2-POP5 grown in SC–Ura medium. The X-axes indicate the mRNA level of 
each gene obtained by RNA-seq (mean counts in RNA-seq). The translational efficien-
cy of each gene was calculated by dividing the ribosome density by the mRNA level. 
The mean fold changes relative to the Single condition were calculated from two bio-
logical replicates. 
(C) Bar graph indicates the mRNA level and translational efficiency of POP5 shown in 
Figure 3.6A and 3.6B.  
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Chapter 4 
 
Biological role of post-translational dosage compensation 
 
4.1 Introduction 
The screen of chromosome I identified five dosage-compensated genes, and interest-
ingly, all screened genes encode subunits of different complexes. As listed in Table 4.1, 
functional similarities were not found among these complexes. This result is in agree-
ment with the previous findings that protein levels for duplicated genes encoding com-
plex subunits tend to be reduced in aneuploid S. cerevisiae strains [19,25]. A similar 
observation was also reported in wild-type Schizosaccharomyces pombe carrying high 
copy numbers of subunit genes [35]. Furthermore, some ribosomal proteins were shown 
to be unstable and rapidly degraded if they are not assembled into a ribosomal complex 
[57]. Indeed, a very recent study has shown that overexpressed ribosomal proteins are 
subjected to protein-level dosage compensation through rapid degradation [58]. This 
study has also shown that overexpressed ribosomal proteins are not assembled into ri-
bosomes, which strongly suggests that dosage compensation affects not only subunit 
levels but also complex levels. On the other hand, there is a previous study showing a 
general lack of dosage compensation [59]. This study used a series of diploid S. cere-
visiae strains lacking one of the two alleles of each gene, and measured the protein level 
expressed from only one allele. More than 700 genes were tested with this experimental 
setup. This analysis showed that for at least 80% of the tested genes, their protein levels 
were close to 50% of those in wild-type strain and that for less than 5% of the ones, the 
protein levels were almost same as those measured in wild-type strain. This small subset 
of the compensated genes is not enriched in genes encoding subunits of protein com-
plexes, and hence correlation between dosage compensation and complex subunits was 
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not found. As described above, it is open question whether complex subunits are pre-
dominant targets of protein-level dosage compensation. Therefore, in this study, I ex-
amined the relationship between complex subunits and dosage compensation using the 
same method that was developed for the screening of the dosage-compensated genes. 
 Genetic perturbations to the stoichiometry of complex subunits are strongly 
suggested to cause growth impairment due to an imbalance of subunit stoichiometry 
[10,13,18,26]. Given that complex subunits are predominantly targeted by dosage com-
pensation, its biological role is expected to circumvent stoichiometric imbalance in mul-
ti-subunit complex. Experimental evidence for a regulation of complex levels by dosage 
compensation may provide a reasonable explanation for this hypothesis. In this study, I 
performed an analysis of not only subunit levels but also complex ones in order to ex-
amine whether dosage compensation contributes to robust formation of a protein com-
plex. 
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4.2 Materials and Methods 
4.2.1 Strains 
The yeast strains BY4741 and tma46∆ (MATa tma46∆::KanMX his3∆1 leu2∆0 
met15∆0 ura3∆0) were used for the protein complex analysis. The TAP tag-encoding 
sequence was integrated into the 3´-region of each gene [33]. These strains were trans-
formed with empty vector pTOWug2-836 or the same vector carrying the gene of inter-
est. Transformation of the yeast strains was performed by the lithium acetate method as 
described above. 
 
4.2.2 Growth media and conditions 
The yeast strains BY4741 and tma46∆ without plasmid were grown at 30 °C in YPD 
medium. These strains with plasmid were grown at 30 °C in SC–Ura or SC–Leu–Ura 
media. 
 
4.2.3 CHX chase assay 
Yeast cells were grown to log-phase in SC–Ura, and 0.5 OD600 units were harvested for 
time point 0. Then, CHX was added to a final concentration of 200 µg/mL. Cells were 
harvested after 1, 2, 4, and 6 h of CHX treatment, followed by total protein extraction in 
2× NuPAGE LDS Sample Buffer. The supernatant corresponding to 0.1 OD600 units was 
analyzed by Western blotting against the TAP tag as described above. The protein level 
at each time point was calculated as the intensity of Rbg1-TAP from Western blot di-
vided by that of the 50-kDa protein, corresponding to enolase, from SDS-PAGE. The 
relative level was calculated by dividing the protein level at each time point by that at 
time point 0. 
 
4.2.4 Native-PAGE analysis 
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Yeast cells were grown to log-phase in 6 mL of the appropriate medium and 5 OD600 
units were harvested. The cells were washed with 1 mL of sterile water and lysed with 
glass beads in 250 µL of Digitonin buffer [1% Digitonin (Invitrogen), 1× NativePAGE 
Sample Buffer (Invitrogen), Protease Inhibitor Cocktail, EDTA-Free]. The supernatant 
corresponding to 0.2 OD600 units was mixed with NativePAGE 5% G-250 Sample Ad-
ditive (Invitrogen) (final concentration 0.25%) and loaded on NativePAGE 4–16% 
Bis-Tris Gel (Invitrogen). The native gel electrophoresis was performed at room tem-
perature with NativePAGE Running Buffer Kit (Invitrogen) according to the manufac-
turer’s instructions. After electrophoresis, the gel was treated with SDS buffer [1× Nu-
PAGE MOPS SDS Running Buffer (Invitrogen), 1% SDS] for 15 min. The gel was 
washed five times with 1× NuPAGE MOPS SDS Running Buffer, and then, blotted on-
to PVDF membrane using the iBlot system. After blotting, the membrane was washed 
with methanol for 5 min for three times, rinsed with PBST [1× PBS, 0.1% Tween 20] 
for three times, and washed in PBST for 10 min. The membrane was blocked with 4% 
skim milk in PBST for 1 h at room temperature before incubation with PAP (1:4000) in 
the same condition. Chemiluminescence was induced and detected as described above. 
The membrane was stained with CBB-R250 after immunoblotting. 
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4.3 Results 
4.3.1 Complex subunits are predominant target of dosage compensation 
Again, I note that all the five dosage-compensated genes identified by the chromosome 
I screen encode subunits of protein complexes as listed in Table 4.1. To investigate the 
relationship between dosage compensation and complex subunits, I analyzed other 
subunits of the same complexes. As shown in Figure 4.1, I found that six of seven sub-
units of the RNase MRP and nuclear RNase P complexes, NSL1 in the MIND complex, 
and EMP24 in the Erp2 complex were compensated at the protein level but not at the 
mRNA level. Quantification showed that the degree of compensation is very similar 
among the six subunits of the RNase MRP and nuclear RNase P complexes (Figure 
4.1B). As listed in Table 4.2 and Figure 4.1D, I tested an additional 12 subunit genes 
and identified 7 dosage-compensated ones. This ratio is significantly higher than that 
identified in the initial screening (5 out of 54 genes) (p < 10−9, chi-square test), although 
not all subunit genes are compensated. Thus, I speculated that dosage compensation 
predominantly targets complex subunits. 
 
4.3.2 Model for maintaining subunit stoichiometry in the Rbg1–Tma46 heterodi-
mer 
As shown above, dosage compensation may be performed mainly through protein deg-
radation and target predominantly complex subunits. Thus, I hypothesized that acceler-
ated degradation of excess subunits that failed to construct a stable complex is the na-
ture of dosage compensation. To test this, I focused on the Rbg1–Tma46 complex as a 
model complex. A working hypothesis is that when a subunit is overexpressed, there are 
two pools of subunit, the unstable pool that has not found a dimerization partner and the 
stable pool that is in a complex (Figure 4.2). The unstable pool is present but very small 
in the native condition where a large fraction of Rbg1 molecules are stable and a stoi-
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chiometric balance between Rbg1 and Tma46 is in the steady state. In contrast, when 
Rbg1 is overexpressed, the unstable pool of Rbg1 is predominant. In the unstable pool, 
accelerated degradation of excess subunits should be observed. 
 
4.3.3 Accelerated degradation of the dosage-compensated protein Rbg1 
I first assessed the degradation of Rbg1 upon its overexpression by measuring the 
amount of Rbg1 after treating cells with a translational inhibitor, CHX. The CHX chase 
assay showed accelerated degradation of Rbg1 when its gene copy number was in-
creased (Figure 4.3A and 4.3B), as I expected. 
 
4.3.4 Bidirectional dosage compensation of Rbg1 in response to changes in gene 
dosage of its partner subunit Tma46 
Next, I tested the effect of a loss and high copy number of TMA46 on Rbg1 expression. 
In tma46∆ strain, the Rbg1 expression was reduced to less than 0.5-fold (Figure 4.3C 
and 4.4A). On the other hand, the amount of Rbg1 was increased more than 1.3-fold 
when the TMA46 copy number was increased in wild-type cells (Figure 4.3D and 4.4B). 
These compensations are performed post-transcriptionally because the RBG1 mRNA 
levels were not changed in these conditions (Figure 4.3C and 4.3D). 
 
4.3.5 Dosage compensation through accelerated proteolysis buffers genetic per-
turbations to subunit stoichiometries at the complex level 
To examine whether dosage compensation directly contributes to a higher or lower lev-
els of the resulting complexes, the levels of the Rbg1–Tma46 complex were assessed by 
Native-PAGE followed by immunoblotting. This analysis confirmed that the complex 
was almost not detected in tma46∆ strain (Figure 4.3E). In wild-type cells, the levels of 
the TAP-tagged version of the Rbg1–Tma46 complex decreased and increased upon an 
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increase in RBG1 and TMA46 copy numbers, respectively (Figure 4.3F). These changes 
in the complex levels are consistent with the changes in the Rbg1 monomer levels in the 
same conditions.  
 The reduction of Rbg1 expression was recovered when TMA46 copy number 
was increased in tma46∆ strain (Figure 4.5A). Quantification showed that the level of 
Rbg1 was significantly higher than that expressed in the same strain under the sin-
gle-copy condition (Figure 4.5B and 4.6). The mRNA level of RBG1 did not differ be-
tween them (Figure 4.5C). Furthermore, Native-PAGE analysis revealed that the level 
of the Rbg1–Tma46 complex also increased in tma46∆ strain upon an increase in 
TMA46 copy number (Figure 4.5D). Therefore, I conclude that Rbg1 stability is modu-
lated depending on the dosage balance against the partner molecule Tma46 and that 
dosage compensation affects not only subunit levels but also complex levels. 
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4.4 Discussion 
Since all screened genes encode subunits of different complexes (Table 4.1), I examined 
whether other subunits of the complexes are subjected to dosage compensation. As a 
result, for 17 subunits included in these complexes, 70% (12 subunits) are subjected to 
dosage compensation (Figure 4.1 and Table 4.2). Given that the biological function of 
dosage compensation is to maintain subunit stoichiometry, these results explain the pre-
vious observation that cellular systems are very fragile to subunit gene overexpression 
[18]. This is also consistent with previous observations that the stoichiometric imbal-
ance caused by aneuploidy strongly correlates with impaired cell growth [44,46]. Simi-
larly, the findings from this study support a classical hypothesis called the balance hy-
pothesis that predicts deleterious effects due to imbalanced subunit stoichiometry [26]. 
Although the screen of chromosome I suggests that the dosage-compensated 
genes encoding complex subunits constitute approximately 10% of the genome, subunit 
genes constitute 33% of the yeast genome. This suggests that there are other rules to 
distinguish between the compensated subunits and the uncompensated ones. Pop8 might 
be helpful for further characterization of the dosage compensation mechanism since the 
compensation level of only Pop8 differed from those of all other tested subunits of 
RNase MRP and nuclear RNase P complexes (Figure 4.1). Pop8 has the smallest num-
ber of interacting partners in these complexes, although the other subunits have at least 
two or more potential partners [60,61]. Therefore, Pop8 is suggested to be located at the 
peripheral region of these complexes. It is also known that only depletion of the Pop8 
does not result in deleterious effects on RNase MRP function [61–66]. A similar obser-
vation in a different protein complex, oligosaccharyl transferase (OST), was recently 
reported [67]. The OST complex consists of nine subunits, including the functionally 
redundant Ost3 or Ost6 components, which are potentially the last subunit assembled 
into the complex. Overexpression of Ost3 or Ost6 does not lead to reduction of its pro-
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tein level, whereas many of the other subunits show accelerated degradation upon their 
overexpression. Moreover, deletion of the Ost3 or Ost6 gene does not affect the protein 
level of the other subunits and results in only a small decrease in enzyme activity of the 
OST complex [67–69]. As listed above, characteristic features with similarities between 
Pop8 and Ost3 or Ost6 include the order of assembly, number of interactions, and re-
sponsibility for the function of each complex. Consideration of these features seems to 
provide other rules to determine the complex subunits predominantly regulated by dos-
age compensation. 
As shown in Figure 4.3, the compensation of Rbg1 is performed in a stoichi-
ometry-dependent manner between gene dosage of RBG1 and TMA46. This bidirection-
al regulation of Rbg1 level may reflect changes in its degradation rate (Figure 4.3A and 
4.3B). These results are analogous to bidirectional changes of Cog1 level upon overex-
pression of itself or its partner subunits: Cog2, Cog3, and Cog4 [70]. 
There are previous studies showing changes in the levels of the dos-
age-compensated subunits upon overexpression of themselves or their partner subunits. 
From these observations, dosage compensation has been postulated to contribute to the 
levels of subunits and also resulting complexes. However, no direct evidence has been 
reported for changes in the level of a complex by dosage compensation of its subunit. In 
this study, I performed Native-PAGE and immunoblotting to assess the levels of the 
dosage-compensated subunit Rbg1 and the Rbg1–Tma46 complex. This experiment in-
dicates that dosage compensation of Rbg1 affects the levels of the Rbg1–Tma46 com-
plex (Figure 4.3E and 4.3F) and that changes in the complex levels are consistent with 
those in the Rbg1 monomer levels. Therefore, I obtained direct experimental evidence 
that dosage compensation affects not only subunit levels but also complex levels.  
 73 
4.5 Tables 
 
Table 4.1. All screened genes encoding subunits of multi-protein complexes. 
 
  
Gene Annotation in Saccharomyces Genome Database 
RBG1 Member of the DRG family of GTP-binding proteins; associates with trans-lating ribosomes; interacts with Tma46p 
MTW1 Essential component of the kinetochore complex; complex consists of Mtw1p including Nnf1p-Nsl1p-Dsn1p (MIND) 
POP5 Subunit of RNase MRP and nuclear RNase P; RNase MRP cleaves pre-rRNA, while nuclear RNase P cleaves tRNA precursors 
SAW1 5'- and 3'-flap DNA binding protein; complexes with Rad1p-Rad10p and stimulates its endonuclease activity 
ERP2 Member of the p24 family involved in ER to Golgi transport; forms a het-erotrimeric complex with Erp1p, Emp24p, and Erv25p 
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Table 4.2. Relationship between dosage compensation and complex subunits. 
a This number includes only protein subunits, not RNA subunits. 
b This number does not include subunits whose protein expression is not detected. 
  
Gene Complex Subunita Tested subunitb 
Compensated 
subunit Reference 
RBG1 Rbg1–Tma46 2 2 1 [71] 
MTW1 
Mtw1–Nnf1–
Nsl1–Dsn1 
(MIND) 
4 3 2 [72] 
POP5 RNase MRP and nuclear RNase P 10 7 6 [60] 
SAW1 Saw1–Rad1–Rad10 3 1 1 [73] 
ERP2 Erp2–Erp1–Emp24–Erv25 4 4 2 [74] 
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4.6 Figures 
 
 
 
 
D 
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Figure 4.1. Complex subunits tend to be subjected to dosage compensation. 
(A) Western blots of subunits composed of the five complexes. The experiments were 
performed using the same method with the screening. TAP-tagged target proteins ex-
pressed from the genomic regions were detected with PAP. The dosage-compensated 
proteins identified from the screening are shown in bold letters. 
(B) Quantification of protein expressions of the subunit genes. 
(C) Quantification of mRNA expressions of the subunit genes. The mRNA level of each 
TAP-tagged target gene was measured as described above. Dashed line denotes the 
same expression level between the Multi and Single conditions. The RNase MRP and 
nuclear RNase P subunit genes were analyzed in three biological replicates, and the av-
erage fold changes ± s.d. were calculated relative to the Single condition. ND: not de-
tected. 
(D) An overview of the analysis of the five complexes and the results shown in Figure 
4.1A and 4.1B. For 17 subunit genes tested, 12 were subjected to dosage compensation. 
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Figure 4.2. Model for maintaining subunit stoichiometry in the Rbg1–Tma46 het-
erodimer. 
(A) Under native conditions, monomeric Rbg1 becomes more stable when it forms a 
complex with Tma46. 
(B) Upon deletion of TMA46, Rbg1 is destabilized due to a loss of the partner subunit 
and rapidly degraded. The unstable pool of Rbg1 is predominant in this condition. 
(C) Upon multicopy expression of Rbg1, the level of the unstable form of Rbg1 is in-
creased, which is targeted for rapid degradation. The unstable pool of Rbg1 is predomi-
nant in this condition. 
(D) Upon multicopy expression of Tma46, potentially degraded Rbg1 is stabilized by 
forming the Rbg1–Tma46 complex with an excess of Tma46. The stable pool of Rbg1 
is predominant in this condition.  
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Figure 4.3. Dosage compensation through accelerated proteolysis buffers genetic 
perturbations to subunit stoichiometries at the complex level. 
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(A) Rbg1-TAP expressed in the Single and Multi conditions was detected by Western 
blotting with PAP after CHX treatment. A 50-kDa protein, corresponding to enolase, is 
used as a loading control. 
(B) Quantification of the degradation of Rbg1-TAP. Percentage of the Rbg1-TAP level 
at each time point relative to the time point 0 is shown. The average expression levels ± 
s.d. were calculated from three biological replicates. 
(C) The effect of TMA46 deletion on Rbg1 expression. Rbg1-TAP expressed in 
wild-type and tma46∆ cells grown in YPD medium was detected by Western blotting 
with PAP (upper panel), and the fold changes were calculated (lower panel). The 
mRNA levels were measured as described above. The average fold changes ± s.d. from 
three biological replicates were calculated relative to the wild-type strain. 
(D) The effect of multicopy TMA46 on Rbg1 expression. Rbg1-TAP expressed under 
the Single (+Vector) and Multi (+RBG1: multicopy of RBG1, +TMA46: multicopy of 
TMA46) conditions were detected by Western blotting with PAP (upper panel), and the 
fold changes were calculated (lower panel). The mRNA levels were measured as de-
scribed above. These cells were grown in SC–Leu–Ura to increase the plasmid copy 
number. The average fold changes ± s.d. of mRNA and protein levels relative to the 
Single condition were calculated from three and six biological replicates, respectively. 
Dashed line denotes the same expression level between the Multi and Single conditions. 
Statistical significance was determined by a one-tailed Mann Whitney U test (*P = 0.05, 
**P < 0.03). 
(E, F) The effect of TMA46 deletion (E) and multicopy of RBG1 or TMA46 (F) on the 
levels of the Rbg1–Tma46 complex. The wild-type and tma46∆ cells without the plas-
mids and wild-type cells with the plasmids were grown in YPD and SC–Ura media, re-
spectively. Rbg1-TAP and Rbg1-TAP–Tma46 expressed in these cells were detected by 
Native-PAGE followed by immunoblotting with PAP. Left: immunoblotting with PAP. 
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Right: total protein blotted onto the membrane and stained with CBB R250. A repre-
sentative blot from two biological replicates is shown. 
  
 81 
 
 
Figure 4.4. Bidirectional changes in Rbg1 level in response to TMA46 copy num-
ber. 
(A) The effect of TMA46 deletion on Rbg1 expression. Rbg1-TAP expressed in 
wild-type and tma46∆ cells grown in YPD medium was detected by Western blotting 
with PAP, and the fold changes were calculated relative to the wild-type strain. All data 
points of Figure 4.3C are shown. 
(B) The effect of multicopy TMA46 on Rbg1 expression. Rbg1-TAP expressed under 
the Single (+Vector) and Multi (+RBG1: multicopy of RBG1, +TMA46: multicopy of 
TMA46) conditions were detected by Western blotting with PAP, and the fold changes 
were calculated relative to the Single condition. All data points of Figure 4.3D are 
shown.  
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Figure 4.5. Multicopy of TMA46 leads to an increase in the level of Rbg1 monomer 
and the Rbg1–Tma46 complex in tma46∆ strain. 
(A) The effect of high copy TMA46 on Rbg1 expression in tma46∆ strain. Rbg1-TAP 
expressed under the Single (+Vector) and Multi (+RBG1: multicopy of RBG1, 
+TMA46: multicopy of TMA46) conditions in wild-type and tma46∆ cells grown in SC–
Ura medium were detected by Western blotting with PAP. 
(B) Quantification of the data shown in Figure 4.5A. The fold change was calculated 
relative to the expression level in wild-type cells under the Single condition. Bar graphs 
show the average fold changes ± s.d. from five biological replicates. P value was deter-
mined by a one-tailed Mann Whitney U test. Dashed line denotes the expression level in 
wild-type cells under the Single condition. 
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(C) The mRNA levels of RBG1 in each of the indicated conditions were measured as 
described above. The average fold changes ± s.d. were calculated from five biological 
replicates. 
(D) Rbg1-TAP and Rbg1-TAP–Tma46 expressed in tma46∆ cells under the indicated 
conditions were detected by Native-PAGE followed by immunoblotting with PAP. Left: 
immunoblotting with PAP. Right: total protein blotted onto the membrane and stained 
with CBB R250. A representative blot from two biological replicates is shown. 
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Figure 4.6. A significant tendency for the increased level of Rbg1 in tma46∆ strain 
carrying high copy numbers of TMA46. 
The effect of high copy TMA46 on Rbg1 expression in tma46∆ strain. Bar graphs show 
the level of Rbg1-TAP expressed under the Single (+Vector) and Multi (+TMA46: mul-
ticopy of TMA46) conditions in tma46∆ cells. All data points of Figure 4.5B are shown. 
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Chapter 5 
 
General discussion 
 
5.1 Post-translational dosage compensation regulates gene expression level at the 
final step of gene expression 
This study extends our understanding of the rescue mechanism for perturbations caus-
ing the breakdown of biological systems. This study demonstrates that protein-level 
dosage compensation is responsible for robust expression of subunit genes under ge-
netic perturbations. Correction of the subunit levels is performed at the final step in 
gene expression by protein degradation rather than earlier steps, mRNA transcrip-
tion/degradation or translation. These results suggest that dosage compensation at the 
post-translational level is a critical step to mask the fragility caused by an increase in 
gene copy number. Furthermore, these findings in the context of systems biology 
provide a new foundation for the robustness of cellular systems. 
 
5.2 The differences between the analysis of aneuploid cells and the gTOW analysis 
The robustness in cellular systems to gene copy number changes has been investigated 
mainly using two approaches: generating aneuploidy of specific chromosomes [19,44] 
and introducing a plasmid carrying an individual target gene [18]. The generation of 
aneuploid cells containing one extra chromosome doubles the number of genes in the 
additional chromosome. Several recent studies using aneuploid yeast and mammalian 
cells have revealed fragility of cellular systems against gene copy number increase in a 
genome-wide manner [19,44]. The use of a multicopy plasmid carrying an individual 
target gene dramatically increases its copy number. A particular method for this ap-
proach is based on the gTOW technique [18]. The genome-wide gTOW analysis has 
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revealed over 80% of the yeast genome with more than 100 copies of an upper limit of 
gene copy number. 
The impact of an increase in gene copy number on cell fitness differs between 
doubled number of genes in an extra chromosome and many copies of a single gene. 
Previous studies have demonstrated that aneuploidy-induced proteotoxic stress causes 
cell fragility leading to growth impairment [15,24,25]. Because aneuploid yeast strains 
are very sensitive to perturbations at the RNA and protein levels, aneuploidy-induced 
proteotoxicity affects a wide range of biological processes. On the other hand, overex-
pression of most individual genes does not inhibit growth of wild-type yeast strain 
[17,18]. Thus, the gTOW technique allows us to study mechanisms for buffering 
against genetic perturbations by focusing on individual target genes in normal physio-
logical condition. I expected that exploring the effects of an increase in individual gene 
copy number identifies novel mechanisms for maintaining cellular homeostasis. Indeed, 
a very recent study has shown that the fragility of aneuploid cells is caused by many 
genes on single additional chromosomes but not by duplicated dosage-sensitive genes 
that were identified by the gTOW analysis [23]. This study identified Mtw1 and Rpp1 
as the dosage-compensated proteins that are not compensated in aneuploid cells [19]. 
This difference may result from aneuploidy-specific physiological conditions associated 
with proteotoxicity. 
 
5.3 Quality control mechanisms for the assembly of multi-protein complexes 
Recent studies investigating the robust formation of protein complexes have elucidated 
the location where subunits are translated [75,76], the timing when subunits are assem-
bled into complexes [77], and the mechanisms by which subunit stoichiometry is main-
tained [30,70]. In agreement with previous studies [15,53,67,70,78,79], this study sug-
gests the biological role of dosage compensation as robust formation of protein com-
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plexes. Furthermore, this study identifies proteasomal degradation as a mechanism of 
the compensation and provides direct evidence for the ubiquitination of the individual 
dosage-compensated proteins (Figure 3.2C). Thus, these findings enhance our under-
standing of dosage compensation as a mechanism for the fine-tuning of subunit levels. 
Protein-level dosage compensation seems to occur cotranslationally for the 
following reasons: (i) subunits are assembled into complexes cotranslationally [77], (ii) 
a large proportion of the proteome is cotranslationally ubiquitinated [80,81], and (iii) 
the degradation of subunits via an N-terminal acetylation at the nascent chain level has 
been supported by experimental evidence [70]. Because N-terminal acetylation is pro-
posed to function as a degradation signal, a global analysis of N-terminal acetylation of 
proteins under genetic perturbations might provide insight into the sensing mechanism 
of the imbalance in subunit stoichiometries in complexes. Proteins containing 
N-terminal acetylation are targeted by the N-end rule pathway and subsequently 
polyubiquitinated and degraded through the ubiquitin–proteasome system [70,82]. Since 
polyubiquitination and proteasomal degradation of the dosage-compensated proteins are 
shown in this study, the analysis of N-terminal acetylation of these proteins may be 
helpful to investigate the contribution of the N-acetyltransferase to dosage compensa-
tion. 
 
5.4 Concluding remark 
Previous study has demonstrated that protein synthesis rate has correlation with stoi-
chiometry of subunits in multi-protein complexes [30]. However, this study has also 
shown that some subunits are synthesized in excess, which indicates that translational 
control is not enough to guarantee subunit stoichiometry. Because some studies suggest 
that an imbalance in subunit stoichiometry relates with a decrease in cellular fitness 
[13,18,19,26], the cell should remove excess subunits in order to maintain cell growth. 
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As shown in this study, protein-level dosage compensation predominantly targets and 
degrades excess subunits through the ubiquitin–proteasome system. Therefore, dosage 
compensation may provide a reasonable explanation for maintenance of subunit stoi-
chiometry. Here, I propose the two-layer mechanism for maintaining the correct stoi-
chiometry of complex subunits (Figure 5.1). This two-layer mechanism seems to func-
tion as the fail-safe mechanism conferring robustness to cell systems. For validation of 
this model, it is critical to examine whether Srp54 and Sec65, subunits of signal recog-
nition particle synthesized in excess [30], are subjected to dosage compensation. 
 This study has focused on the effects of gene copy number alterations on cel-
lular robustness, and I applied the gTOW technique in order to manipulate and perturb 
gene expression. With this approach, I aimed to understand the mechanism for buffering 
against genetic perturbations and the quantitative aspects of the central dogma of mo-
lecular biology in the context of robustness. Although gene copy number was artificial-
ly increased in this study, changes in gene copy number are a common feature not only 
in disease conditions but also in physiological ones. Therefore, the implications of dos-
age compensation should be regarded as the potential contribution to cell robustness. 
Indeed, a very recent study has suggested that dosage compensation buffers the effect of 
transient changes in gene dosage during DNA replication on the resulting expression 
levels [83]. This study has shown that mRNA levels of early-replicating genes are 
down-regulated by acetylation of histone H3 K56 by Rtt109 and Asf1 and that the re-
duced mRNA levels are similar to those of late-replicating genes in S. cerevisiae. This 
observation suggests that dosage compensation has the broad impact on gene expression 
levels and implies that cells have to cope with gene-dosage imbalance, which is re-
viewed in [84].  
A previous study has shown the possibility of manipulating dosage compen-
sation in a chromosome-wide manner [85]. This study used induced pluripotent stem 
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cells derived from a Down’s syndrome patient and introduced XIST gene, which is re-
sponsible for X-chromosome inactivation in mammalian cells, into one of the three 
chromosome 21 in the cells. Surprisingly, this resulted in widespread silencing of 
chromosome 21 at the mRNA level, indicating that this experiment has demonstrated 
translating dosage compensation to trisomy 21. One possible way to validate the con-
trollability of the chromosome-wide dosage compensation is to examine the effects of 
the introduction of XIST gene to an aneuploid chromosome in cancer cells on gene ex-
pression levels from the target chromosome carrying XIST gene. If the gene expression 
levels are down-regulated, it may be strong evidence for XIST gene-dependent dosage 
compensation. 
I conclude by noting that subunit stoichiometry potentially has a broad impact 
on robustness in cellular systems because of the fact that numerous biological processes 
are dependent on protein complexes. Furthermore, studies of mechanisms behind stoi-
chiometry maintenance might be important for understanding diseases related to gene 
copy number alterations. For example, a recent study suggests that a set of specific 
genes on trisomic chromosome 21 have a causal effect on Down’s syndrome [86]. 
Again, the approach based on the gTOW technique for measuring robustness in cellular 
systems provides a fundamental framework for the quantitative assessment of cell ro-
bustness.  
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5.5 Figure 
 
 
 
Figure 5.1. Model for the fail-safe mechanism contributing to cellular robustness. 
Translational control may be the predominant contribution to a balanced stoichiometry 
of complex subunits. As some studies have pointed out, stoichiometric imbalance may 
cause impaired cell growth, so that when subunits are translated in excess, cells may 
have to cope with the imbalanced stoichiometry. In this situation, protein-level dosage 
compensation may be responsible for regulating subunit stoichiometry in order to cir-
cumvent the growth defect. As this study has shown, the ubiquitin–proteasome system 
contributes to dosage compensation. Therefore, I believe that this two-layer mechanism, 
translational control and the ubiquitin–proteasome system, may function as the fail-safe 
mechanism.  
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